Strenuous Exercise Affects Gout

Strenuous Exercise Affects Gout

by | Nov 20, 2024 | Excercise, Gout

How Does Strenuous Exercise Affect Gout?

  1. Increased Uric Acid Production: During strenuous exercise, the body’s metabolic rate increases, leading to the production of more uric acid. This is because exercise can increase the breakdown of purines, which are then converted into uric acid (Kakutani-Hatayama et al., 2017, pp. 321–329).
  2. Dehydration: Strenuous exercise can lead to dehydration, which reduces the body’s ability to excrete uric acid through the kidneys. When the body is dehydrated, the concentration of uric acid in the blood increases, which can lead to the formation of uric acid crystals (Kakutani-Hatayama et al., 2017, pp. 321–329; Poortmans, 1995, pp. 317–324).
  3. Lactic Acid Production: Intense exercise can also lead to the production of lactic acid, which competes with uric acid for excretion by the kidneys. This competition can result in higher levels of uric acid in the blood (Kakutani-Hatayama et al., 2017, pp. 321–329).
  4. Oxidative Stress: Exercise-induced oxidative stress can exacerbate inflammation in the body. The production of reactive oxygen species (ROS) during strenuous exercise can lead to cellular damage and inflammation, which may trigger a gout flare-up (Chevion et al., 2003, pp. 5119–5123; Liu et al., 1999, pp. E1083–E1091).
  5. Muscle Damage: Strenuous exercise can cause muscle damage, leading to the release of proteins and other substances into the bloodstream. This can increase the body’s inflammatory response, potentially triggering a gout attack (Kakutani-Hatayama et al., 2017, pp. 321–329).

Organ Functions Involved

Kidneys

The kidneys play a crucial role in excreting uric acid from the body. During dehydration or when there is competition from lactic acid, the kidneys may not effectively remove uric acid, leading to its accumulation (Kakutani-Hatayama et al., 2017, pp. 321–329; Poortmans, 1995, pp. 317–324).

  • Filtration: Blood enters the kidneys through the renal arteries, where it is filtered in the glomeruli. Uric acid, along with other waste products, is filtered out of the blood.
  • Reabsorption: After filtration, some uric acid is reabsorbed back into the bloodstream in the renal tubules. This process is regulated by specific transporters, such as URAT1 and GLUT9.
  • Secretion: Uric acid that is not reabsorbed is secreted into the urine for excretion. This process is also regulated by transporters in the renal tubules.
  • Excretion: The final step is the excretion of uric acid in the urine. Adequate hydration is essential for maintaining urine flow and preventing the accumulation of uric acid.

Impact of Strenuous Exercise on Kidney Function

During strenuous exercise, the kidneys undergo several changes:

  • Reduced Blood Flow: Exercise can lead to a temporary reduction in renal blood flow, which can affect the kidneys’ ability to filter and excrete waste products, including uric acid (Poortmans & Vanderstraeten, 1994, pp. 419–437; Trejo et al., 2017, p. 17).
  • Increased Protein Excretion: Strenuous exercise can increase the excretion of proteins in the urine, a condition known as exercise-induced proteinuria (Poortmans & Vanderstraeten, 1994, pp. 419–437).
  • Transient Changes in Renal Function: Exercise can cause transient changes in renal function, such as decreased glomerular filtration rate (GFR) and altered electrolyte balance (Trejo et al., 2017, p. 17).

Liver

The liver is involved in the metabolism of purines. During intense exercise, the liver’s ability to process purines may be overwhelmed, leading to increased uric acid production (Kakutani-Hatayama et al., 2017, pp. 321–329).

  1. Purine Metabolism: The liver is responsible for breaking down purines into uric acid. This process involves several enzymes, including xanthine oxidase, which converts hypoxanthine to xanthine and then to uric acid.
  2. Uric Acid Production: The liver produces uric acid as a byproduct of purine metabolism. This uric acid is then released into the bloodstream, where it can be excreted by the kidneys.
  3. Detoxification: The liver helps detoxify the body by converting harmful substances into less toxic forms. This includes the conversion of excess purines into uric acid for excretion.
  4. Regulation of Blood Uric Acid Levels: The liver helps regulate blood uric acid levels by balancing the production and excretion of uric acid. This is crucial for preventing the accumulation of uric acid crystals in the joints.

Impact of Strenuous Exercise on Liver Function

During strenuous exercise, the liver undergoes several changes:

  • Increased Metabolic Demand: The liver’s metabolic demand increases during exercise, leading to increased production of uric acid.
  • Altered Blood Flow: Exercise can lead to a temporary reduction in blood flow to the liver, affecting its ability to metabolize purines and excrete uric acid.
  • Oxidative Stress: The liver is susceptible to oxidative stress during intense exercise, which can impair its function and exacerbate inflammation.
  1. Muscles: Exercise-induced muscle damage can release substances that increase inflammation, contributing to a gout flare-up (Kakutani-Hatayama et al., 2017, pp. 321–329).

Managing Gout During Exercise

While strenuous exercise can potentially trigger a gout flare-up, it doesn’t mean that people with gout should avoid exercise altogether. Exercise is important for overall health and can help manage weight, which is a risk factor for gout. Here are some tips for managing gout during exercise:

  1. Stay Hydrated: Drinking plenty of water before, during, and after exercise can help flush uric acid from the body and prevent dehydration (Kakutani-Hatayama et al., 2017, pp. 321–329).
  2. Moderate Exercise Intensity: Engaging in moderate-intensity exercise rather than strenuous exercise can reduce the risk of a gout flare-up (Kakutani-Hatayama et al., 2017, pp. 321–329).
  3. Monitor Uric Acid Levels: Regularly monitoring uric acid levels can help manage gout and prevent flare-ups (Kakutani-Hatayama et al., 2017, pp. 321–329).
  4. Consult a Healthcare Provider: Before starting a new exercise regimen, it’s important to consult a healthcare provider, especially if you have gout or other health conditions (Kakutani-Hatayama et al., 2017, pp. 321–329).

Conclusion

Strenuous exercise can lead to a gout flare-up due to increased uric acid production, dehydration, competition for excretion with lactic acid, oxidative stress, and muscle damage. These factors can lead to the accumulation of uric acid in the blood and the formation of uric acid crystals in the joints, triggering inflammation and pain associated with gout. By managing hydration, moderating exercise intensity, and monitoring uric acid levels, individuals can reduce the risk of exercise-induced gout flare-ups and maintain a healthy lifestyle.

Bibliography

(more…)

Gout is Most Common in These Areas

Gout is Most Common in These Areas

by | Nov 20, 2024 | Gout

To understand where gout is most common around the world and why, let’s break it down in a way that’s easy to grasp.

What is Gout?

Gout is a type of arthritis, which is a condition that causes pain and swelling in the joints. It happens when there is too much uric acid in the blood. Uric acid is a substance that forms when the body breaks down purines, which are found in certain foods and drinks. When there is too much uric acid, it can form sharp crystals in the joints, leading to the painful symptoms of gout.

Where is Gout Most Common?

Gout is found all over the world, but some areas have more cases than others. Here are some regions where gout is particularly common:

  1. North America: In countries like the United States, gout is quite common. This is partly because of the diet and lifestyle, which often includes foods and drinks high in purines, like red meat and sugary beverages.
  2. East Asia: Countries like China and Japan have seen an increase in gout cases. This rise is linked to changes in diet and lifestyle as these countries become more developed.
  3. Pacific Islands: In places like New Zealand, especially among the Maori population, gout is more prevalent. This is due to genetic factors and dietary habits.
  4. Europe: Some parts of Europe also report high cases of gout, particularly in countries with diets rich in meat and alcohol.

 

Why is Gout More Common in These Areas?

Several factors contribute to the high prevalence of gout in these regions:

  1. Diet: A diet high in purines can lead to higher levels of uric acid. Foods like red meat, seafood, and sugary drinks are rich in purines. In many developed countries, these foods are consumed frequently, leading to more cases of gout.
  2. Lifestyle: Sedentary lifestyles, where people do not get enough physical activity, can contribute to obesity, which is a risk factor for gout. Many people in developed countries have jobs that require sitting for long periods, and they may not exercise enough.
  3. Genetics: Some populations have a genetic predisposition to gout. This means that they are more likely to develop the condition due to their genetic makeup. For example, the Maori people in New Zealand have a higher genetic risk for gout.
  4. Obesity: Being overweight or obese increases the risk of developing gout. This is because more body fat can lead to higher levels of uric acid. In many developed countries, obesity rates are high, which correlates with higher gout cases.
  5. Alcohol Consumption: Drinking alcohol, especially beer, can increase uric acid levels. In regions where alcohol consumption is high, there are often more cases of gout.
  6. Age and Gender: Gout is more common in men than in women, and it often develops in middle age. However, after menopause, women’s risk increases. This pattern is seen globally.

 

How Can Gout Be Managed?

While gout can be painful, it is manageable with the right approach:

  1. Dietary Changes: Reducing the intake of purine-rich foods can help lower uric acid levels. This means eating less red meat and seafood and avoiding sugary drinks and alcohol.
  2. Weight Management: Maintaining a healthy weight through diet and exercise can reduce the risk of gout attacks.
  3. Medication: There are medications available that can help lower uric acid levels and manage pain during gout attacks.
  4. Hydration: Drinking plenty of water can help flush uric acid from the body.
  5. Regular Check-Ups: Regular visits to a healthcare provider can help monitor uric acid levels and adjust treatment as needed.

 

Conclusion

Gout is a common condition that affects many people worldwide, particularly in regions with diets high in purines and sedentary lifestyles. Understanding the factors that contribute to gout can help in managing and preventing it. By making lifestyle changes and seeking medical advice, individuals can reduce their risk of gout and manage its symptoms effectively.

 

Bibliography:

Ahn, J. (2023). Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean. Journal of Rheumatic Diseases, 30, 88–98.

Al-Allaf, A., & Rheumatologist, C. (1970). Gout: evidence based update with new therapeutic strategies. Sudan Medical Journal.

Alderman, M. (2007). Uric Acid , and Cardiovascular Disease.

AlQahtani, A., Alim, B. M., Almudhaibery, F. S., Mulafikh, D., Almutairi, S., Almohanna, S., & Alfawwaz, F. S. (2022). The Impact of Climatic, Socioeconomic, and Geographic Factors on the Prevalence of Allergic Fungal Rhinosinusitis: A Worldwide Ecological Study. American Journal of Rhinology & Allergy, 36, 423–431.

Araujo Dantas, A. B., Gonçalves, F., Martins, A., Santos Alves, G. Â., Stechman-Neto, J., Corrêa, C., Santos, R., Nascimento, W., Araújo, C. M., & Taveira, K. V. M. (2023). Worldwide prevalence and associated risk factors of obstructive sleep apnea: a meta-analysis and meta-regression. Sleep and Breathing, 27, 2083–2109.

Barbadoro, P., Luciani, A., Ciotti, M., D’Errico, M., & Group, O. B. O. T. A. W. C. (2020). Two-Source Capture-Recapture Method to Estimate the Incidence of Acute Flaccid Paralysis in the Marches Region (Italy). International Journal of Environmental Research and Public Health, 17.

Bardin, T., & Richette, P. (2017). Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Medicine, 15.

Barskova, V. G., & Mukagova, M. V. (2011). Современные представления о патогенезе и методах коррекции уратного нефролитиаза у больных подагрой. Modern Rheumatology Journal, 5, 39–43.

Bozio, P. M. C., Ujamaa, M. D., Dawood, M. F. S., Chai, M. M. S., Kirley, M. P. D., Alden, M. N. B., Austin, M. E., Desiato, M. J., Yousey-Hindes, M. K., EmilyFawcett, M., KyleP.Openo, M., MayaMonroe, M., PatriciaA.Ryan, M., Science Anna Falkowski, M., Kim, M. S., eld, M. R. L., McMahon, M. M., Angeles, M. K., Khanlian, M. S., … Garg, M. S. (2023). 2614. Trends in characteristics of influenza-associated hospitalizations among pregnant women, FluSurv-NET 2015-2016 through 2022-2023 seasons. Open Forum Infectious Diseases, 10.

Broström, A., Alimoradi, Z., Lind, J., Ulander, M., Lundin, F., & Pakpour, A. (2023). Worldwide estimation of restless legs syndrome: a systematic review and meta‐analysis of prevalence in the general adult population. Journal of Sleep Research, 32.

Buckley, H. (2011). Epidemiology of Gout: Perspectives from the Past. Current Rheumatology Reviews, 7, 106–113.

Celermajer, D. (2017). Eisenmenger syndrome: a rare malady that continues to fascinate. European Heart Journal, 38, 2068–2069.

Cheremushkina, E., Eliseev, M., Severinova, M., & Zhelyabina, O. (2023). Sonography as method for diagnosing gout at preclinical stage (preliminary data from pilot study). Medical Alphabet.

Chiarotti, F., & Venerosi, A. (2020). Epidemiology of Autism Spectrum Disorders: A Review of Worldwide Prevalence Estimates Since 2014. Brain Science, 10.

Chikina, M., Ilyinykh, E., & Eliseev, M. (2020). Adherence to urate-lowering therapy while following the national guidelines for the management of patients with gout (preliminary evidence). Modern Rheumatology Journal, 14, 70–75.

Chua, C., & Thong, B. (2021). Inflammatory Arthritis Among Military Servicemen From a Rheumatology Center in Singapore. Military Medicine.

Dehlin, M., Drivelegka, P., Sigurdardottir, V., Svärd, A., & Jacobsson, L. (2016a). Incidence and prevalence of gout in Western Sweden. Arthritis Research & Therapy, 18.

Dehlin, M., Drivelegka, P., Sigurdardottir, V., Svärd, A., & Jacobsson, L. (2016b). THU0522 Increasing Incidence of Gout in Western Sweden – A Register Study. Annals of the Rheumatic Diseases, 75, 381–381.

Denova, L. D. (2023). The effect of antioxidant therapy on the course of predialysis chronic kidney disease in a patient with comorbidity. KIDNEYS.

Donzelli, A., Battaggia, A., & Schivalocchi, A. (2017). Statin use does not protect from fractures: the healthy adherer effect is a plausible explanation in observational studies. Osteoporosis International, 28, 2739–2740.

Dp, M. (1992). [Changes in the epidemiology, symptomatology and prognosis of gout]. Versicherungsmedizin / Herausgegeben von Verband Der Lebensversicherungs-Unternehmen e.V. Und Verband Der Privaten Krankenversicherung e.V, 44, 10–13.

Egami, T., & Ryu, C. W. (2023). Origin of medium-range atomic correlation in simple liquids: Density wave theory. AIP Advances.

Fernández‐Cruz, A., Menárguez, M. C., Muñoz, P., Pedromingo, M., Peláez, T., Solís, J., Rodrı́guez-Créixems, M., Bouza, E., & group. (2015). The search for endocarditis in patients with candidemia: a systematic recommendation for echocardiography? A prospective cohort. European Journal of Clinical Microbiology and Infectious Diseases, 34, 1543–1549.

Freeman, E. (1902). THREE CASES OF CEREBRO-SPINAL FEVER TREATED WITH ANTIPYRIN. British Medical Journal, 1, 1262–1263.

Furuichi, K., Shimizu, M., Yuzawa, Y., Hara, A., Toyama, T., Kitamura, H., Suzuki, Y., Sato, H., Uesugi, N., Ubara, Y., Hoshino, J., Hisano, S., Ueda, Y., Nishi, S., Yokoyama, H., Nishino, T., Kohagura, K., Ogawa, D., Mise, K., … Nephros. (2018). Nationwide multicenter kidney biopsy study of Japanese patients with hypertensive nephrosclerosis. Clinical and Experimental Nephrology, 22, 629–637.

Geedigunta, V., Khan, Z., Bachan, M., Latef, S., Eshak, D., & Dosala, S. (2022). A Unique Case of Pneumocystis Jirovecii (PCP) Pneumonia in HIV- Uninfected, COVID -19 Positive Patient. C61. BREAKING THE MOLD.

Gelsomino, M., & Tamborrini, G. (2014). [Treatment resistant polyarthritis]. Praxis, 103 14, 841–844.

Gill, D., Daniel, R., Halpern, L., & Southerland, J. (2016). A Giant Submandibular Sialolith in the Setting of Chronic Sialodenitis : A Case Report and Literature Review.

Giorgi, A. D., Fabbian, F., Pala, M., Tiseo, R., Parisi, C., Misurati, E., & Manfredini, R. (2015). Uric acid: friend or foe? Uric acid and cognitive function “Gout kills more wise men than simple”. European Review for Medical and Pharmacological Sciences, 19 4, 640–646.

Guizzardi, G., & Guarino, N. (2023). Semantics, Ontology and Explanation. arXiv.Org, abs/2304.11124.

Gupta, R. S., Koteci, A., Morgan, A., George, P., & Quint, J. (2023). Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review. BMJ Open Respiratory Research, 10.

Gupta, S., Yui, J., Xu, D., Fitzhugh, C., Clark, C., Siddiqui, S., Conrey, A. K., Kato, G., & Minniti, C. (2015). Gout and sickle cell disease: not all pain is sickle cell pain. British Journal of Haematology, 171.

Hameed, M., Turkiewicz, A., Englund, M., Jacobsson, L., & Kapetanovic, M. (2019). Prevalence and incidence of non-gout crystal arthropathy in southern Sweden. Arthritis Research & Therapy, 21.

Hancuh, M., Walldorf, J., Minta, A. A., Tévi-Bénissan, C., Christian, K., Nedelec, Y., Heitzinger, K., Mikoleit, M., Tiffany, A., Bentsi-Enchill, A., & Breakwell, L. (2023). Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction — Worldwide, 2018–2022. MMWR. Morbidity and Mortality Weekly Report, 72, 171–176.

Hazlina, N. H. N., Norhayati, M. N., Bahari, I. S., & Arif, N. A. N. M. (2022). Worldwide prevalence, risk factors and psychological impact of infertility among women: a systematic review and meta-analysis. BMJ Open, 12.

He, Q., Mok, T., Sin, T.-H., Yin, J., Li, S., Yin, Y., Ming, W., & Feng, B. (2023). Global, Regional, and National Prevalence of Gout From 1990 to 2019: Age-Period-Cohort Analysis With Future Burden Prediction. JMIR Public Health and Surveillance, 9.

Hor, J. Y., Asgari, N., Nakashima, I., Broadley, S., Leite, M., Kissani, N., Jacob, A., Marignier, R., Weinshenker, B., Paul, F., Pittock, S., Palace, J., Wingerchuk, D., Behne, J., Yeaman, M., & Fujihara, K. (2020). Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Frontiers in Neurology, 11.

Hor, J. Y., & Fujihara, K. (2023). Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Frontiers in Neurology, 14.

Huang, J., Chan, W. C., Ngai, C., Lok, V., Zhang, L., Lucero‐Prisno, D., Xu, W., Zheng, Z., Elcarte, E., Withers, M., Wong, M. C. S., & A, O. B. O. N. G. H. R. G. O. (2022). Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers, 14.

Ijms, E. B. (2022). Abstracts of the Medical Academical Conference of Piauí (COMAPI) 2021. International Journal of Medical Studies.

Iqbal, U., Siddiqui, H. U., Anwar, H., Chaudhary, A., & Quadri, A. (2017). Allopurinol-Induced Granulomatous Hepatitis: A Case Report and Review of Literature. Journal of Investigative Medicine High Impact Case Reports, 5.

Jiang, J., Zhang, T., Liu, Y., Chang, Q., Zhao, Y., Guo, C., & Xia, Y. (2023). Prevalence of Diabetes in Patients with Hyperuricemia and Gout: A Systematic Review and Meta-analysis. Current Diabetes Reports, 23, 103–117.

Jiang, L., Chen, S., Wu, Y., Zhou, D., & Duan, L. (2023). Prediction of coronary heart disease in gout patients using machine learning models. Mathematical Biosciences and Engineering : MBE, 20 3, 4574–4591.

Johnson, G. (1873). Lectures on the Pathology, Diagnosis, and Treatment of Bright’s Disease. British Medical Journal, 1, 725–726.

Kancherla, V. (2023). Neural tube defects: a review of global prevalence, causes, and primary prevention. Child’s Nervous System, 1–8.

Kawamura, Y., Nakaoka, H., Nakayama, A., Okada, Y., Yamamoto, K., Ooyama, H., Stibůrková, B., Merriman, T., Nakatochi, M., Wakai, K., Kubo, M., Ichida, K., Shinomiya, N., & Matsuo, H. (2019). OP0047 A GENOME-WIDE ASSOCIATION STUDY IDENTIFIED NOVEL LOCI ASSOCIATED WITH THE PROGRESSION FROM ASYMPTOMATIC HYPERURICEMIA TO GOUT. Oral Presentations, 78, 94–95.

Klerk, E., Heijde, D. M., Tempel, H., & Linden, S. (1999). Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. Journal of Rheumatology, 26 12, 2635–2641.

Knowledge, Attitude and Practices Assessment of the Gout Patients Residing in Lahore, Pakistan. (2022). Pakistan Journal of Medicine and Dentistry.

Kodio, B., Pamanta, I., Sylla, C., Kayentao, K., Dolo, H., & Cissé, I. (2015). Step wise approach of gout in the rheumatology ward of Point-G University Teaching Hospital of Bamako, Mali. 3, 22–26.

Koto, R., Nakajima, A., Horiuchi, H., & Yamanaka, H. (2019). FRI0678 PREVALENCE, PATIENT CHARACTERISTICS, AND TREATMENT OF GOUT AND ASYMPTOMATIC HYPERURICEMIA IN JAPAN: CROSS-SECTIONAL STUDY OF A HEALTH INSURANCE CLAIMS DATABASE. Epidemiology, Risk Factors for Disease or Disease Progression, 78, 1037–1037.

Kuo, C., Grainge, M., See, L., Yu, K.-H., Luo, S., Zhang, W., & Doherty, M. (2015). Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Research & Therapy, 17.

Lee, E., Knox, C., & Phillips, E. (2023). Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatology.

Lee, J., Lee, J. S., Chung, M., Ahn, J., Choi, H., Hong, S.-J., Yoon, C., Kim, S.-H., Jeong, K.-H., Kim, J.-W., Kim, B.-Y., Shin, J., Kim, W., Kim, S., Kim, H.-J., Song, J.-S., Jun, J.-B., Park, H.-A., Chae, S., … Kim, H. A. (2023). Korean guidelines for the management of gout. Journal of Rheumatic Diseases, 30, 141–150.

Lerma, O., Kosheleva, O., & Kreinovich, V. (2014). A Simple Geometric Model Provides a Possible Quantitative Explanation of the Advantages of Immediate Feedback in Student Learning.

Li, F., Qin, W., Zhu, M., & Jia, J. (2021). Model-Based Projection of Dementia Prevalence in China and Worldwide: 2020-2050. Journal of Alzheimer’s Disease.

Li, H., Nie, D., Wang, S., Li, D., & Liu, C.-H. (2021). Clinical value of turbidity-elimination gout soup combined with external application of traditional chinese medicine to improve the pain and the volume of tophi in patients with gout. Food Science and Technology International.

Maggioni, A., Rossi, E., Cinconze, E., Roggeri, D., Roggeri, A., Fabbri, G., Rosa, M., & Arno Cardiovascular Observatory. (2013). Outcomes, Health Costs and Use of Antiplatelet Agents in 7,082 Patients Admitted for an Acute Coronary Syndrome Occurring in a Large Community Setting. Cardiovascular Drugs and Therapy, 27, 333–340.

Martínez-Martínez, M., Román-Acosta, S., Alvarez-Reyes, J., Oros-Ovalle, C., & Abud-Mendoza, C. (2013). [Calciphylaxis, renal failure and gout. A patient with hyperuricemia as a risk factor for death]. Revista Medica Del Instituto Mexicano Del Seguro Social, 51 2, 218–221.

Mattiuzzi, C., & Lippi, G. (2019). Recent updates on worldwide gout epidemiology. Clinical Rheumatology, 39, 1061–1063.

Mémin, Y., Monville, C., & Ryckewaert, A. (1978). [Articular chondrocalcinosis after 80 years of age]. Revue Du Rhumatisme et Des Maladies Osteo-Articulaires, 45 2, 77–82.

Mertz, D. (1992). [Changes in the epidemiology, symptomatology and prognosis of gout]. Versicherungsmedizin, 44 1, 10–13.

Mittal, G., Oncologist, S., Manjunath, S., Naik, B. N., Deb, S., & Pathology, O. (2020). Clinico-pathological co-relation using various immuno-histochemistry markers likeER, PR, HER-2 NEU, CK5/6, EGFR, KI-67 in carcinoma breast. 5, 30–34.

Moorthie, S., Blencowe, H., Darlison, M. W., Lawn, J., Morris, J., Modell, B., Bittles, A., Blencowe, H., Christianson, A., Cousens, S., Darlison, M. W., Gibbons, S., Hamamy, H., Khoshnood, B., Howson, C., Lawn, J., Mastroiacovo, P., Modell, B., Moorthie, S., … Yunnis, K. A. (2018). Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide. Journal of Community Genetics, 9, 387–396.

Nicholson, P., Saunsbury, E., D’Angelo, S., Churchill, D., & Walker-Bone, K. (2018). Prevalence of and risk factors for gout in HIV-positive adults: A case–control study. International Journal of STD and AIDS, 30, 249–255.

Nkeck, J., Singwé-Ngandeu, M., Moor, V., Chedjou, J.-P., Doualla, M., & Mbacham, W. (2017). Evaluation of Oxidative Status of Patients with Gout Attack in a Cameroonian Urban Hospital. Open Journal of Rheumatology and Autoimmune Diseases, 07, 111–119.

Parchami-Araghi, A., Bohle, M., Rao, S., & Schiele, B. (2024). Good Teachers Explain: Explanation-Enhanced Knowledge Distillation. arXiv.Org, abs/2402.03119.

Pillinger, M., & Abeles, A. (2010). Such Sweet Sorrow: Fructose and the Incidence of Gout. Current Rheumatology Reports, 12, 77–79.

Pirog, E., Lloveras, B., Molijn, A., Tous, S., Guimerà, N., Alejo, M., Clavero, O., Klaustermeier, J., Jenkins, D., Quint, W., Bosch, F., Alemany, L., & Sanjosé, S. (2014). HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Modern Pathology, 27, 1559–1567.

Pukdee, R., Sam, D., Kolter, J. Z., Balcan, M.-F., & Ravikumar, P. (2023). Learning with Explanation Constraints. Neural Information Processing Systems, abs/2303.14496.

Rachina, S., Kozlov, R., Kurkova, A., Portnyagina, U., Palyutin, S., Khokhlov, A., Reshetko, O., Zhuravleva, M., Palagin, I., & Project, O. B. O. R. W. G. O. T. (2022). Antimicrobial Dispensing Practice in Community Pharmacies in Russia during the COVID-19 Pandemic. Antibiotics, 11.

Rana, A., D’Addio, R. M., Manzato, M., & Bridge, D. (2022). Extended recommendation-by-explanation. User Modeling and User-Adapted Interaction, 32, 91–131.

Ransome, A. (1883). Progressive Pernicious Anæmia: A Case, with Remarks*. British Medical Journal, 1, 1112–1113.

Redondo-Rodriguez, R., Mena-Vázquez, N., Cabezas-Lucena, A. M., Manrique-Arija, S., Mucientes, A., & Fernández-Nebro, A. (2022). Systematic Review and Metaanalysis of Worldwide Incidence and Prevalence of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis. Journal of Clinical Medicine, 11.

Rees, F., Doherty, M., Grainge, M., Lanyon, P., & Zhang, W. (2017). The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology, 56, 1945–1961.

Roman, Y. M., Tiirikainen, M., & Prom-Wormley, E. (2020). The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. Clinical Rheumatology, 39, 2387–2392.

Russell, E., & Checa, A. (2013). Potential pitfalls in the diagnosis of crystal-induced arthritis and in the sonographic measurement of hyaline cartilage due to the presence of joint effusion. Journal of Clinical Rheumatology, 19 2, 98–100.

Saunsbury, E., Mahendran, P., Youssef, E., Churchill, D., Roddy, E., Packham, J., Obrenovic, K., & Ledingham, J. (2014). PREVALENCE OF AND RISK FACTORS FOR GOUT IN THE HIV-INFECTED POPULATION.

Sigurdsson, E. (2013). Up and running: An underutilized prescription in primary care. Scandinavian Journal of Primary Health Care, 31, 1–2.

Singh, G., Lingala, B., & Mithal, A. (2019a). Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology.

Singh, G., Lingala, B., & Mithal, A. (2019b). SAT0405 GOUT AND HYPERURICEMIA IN THE US: PREVALENCE AND TRENDS. Saturday, 15 June 2019, 78, 1290–1290.

Sparks, S., Vang, P. C., Peterman, B., Moua, M., & Phillips, L. (2014). Commentary: Utilizing Community-Engaged Approaches to Investigate and Address Hmong Women’s Cancer Disparities. Hmong Studies Journal, 15, 1–18.

Sriboonchitta, S., & Kreinovich, V. (2018). Why Are FGM Copulas Successful? A Simple Explanation. Advances in Fuzzy Systems, 2018, 5872195:1-5872195:5.

Teng, M., Ng, C., Huang, D. Q., Chan, K., Tan, D. J. H., Lim, W., Yang, J. D., Tan, E., & Muthiah, M. (2022). Global incidence and prevalence of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 29, S32–S42.

The, W. C. O. T. R. O. C. H. A. (2023). Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary. Biomedical and Environmental Sciences : BES, 36 8, 669–701.

Ting, K., Gill, T., Keen, H., Tucker, G. R., & Hill, C. (2016). Prevalence and associations of gout and hyperuricaemia: results from an Australian population‐based study. Internal Medicine Journal (Print), 46.

Urban, M. (2016). 17. Motivation by formally analyzable terms in a typological perspective: An assessment of the variation and steps towards explanation.

Utkin, L., Meldo, A., Kovalev, M., & Kasimov, E. (2020). A Simple General Algorithm for the Diagnosis Explanation of Computer-Aided Diagnosis Systems in Terms of Natural Language Primitives. System Configuration Management, 202–205.

Vinotha, T. (2015). Association of High Serum Uric Acid Levels in Chronic Liver Disease.

Watson, C. (1905). REASONS FOR ABANDONING THE URIC ACID THEORY OF GOUT. British Medical Journal, 1, 127–129.

West, S. (1911). A Clinical Lecture ON GRANULAR KIDNEY AND ITS SURPRISES. British Medical Journal, 1, 1099–1101.

Wright, C. (1975). An explanation for some aspects of the behaviour of congested road traffic in terms of a simple model. Transportation Research, 9, 267–273.

Wright, S., Chapman, P., Frampton, C., O’Donnell, J., & Raja, R. (2017). The Journal of Rheumatology Management of Gout in a Hospital Setting : A Lost Opportunity and Lisa Stamp.

Xu, H., Qin, H., Hua, Y., & Dalbeth, N. (2023). Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research. Annals of the Rheumatic Diseases, 82, 1511–1515.

Yi-nu, M., & Xin, O. (2009). Progress of High Methylation On Cerical Cancer Related Gene Promoter. Progress in Modern Biomedicine.

Yun-fe, H. (2015). Investigation of the abnormal of serum carbohydrate antigen 724 level in patients with gout. Chinese Journal of Health Laboratory Technology.

Yung-Chen, Lin, C.-S., Hong, C.-F., Lee, D. J., Sun, C., & Lin, H.-H. (2019). Design of a Clinical Decision Support System for Predicting Erectile Dysfunction in Men Using NHIRD Dataset. IEEE Journal of Biomedical and Health Informatics, 23, 2127–2137.

Zeidan, J., Fombonne, E., Scorah, J., Ibrahim, A., Durkin, M., Saxena, S., Yusuf, A., Shih, A., & Elsabbagh, M. (2022). Global prevalence of autism: A systematic review update. Autism Research, 15, 778–790.

Zhang, J., Jin, C., Ma, B., Sun, H., Chen, Y., Zhong, Y., Han, C., Liu, T., & Li, Y. (2023). Global, regional and national burdens of gout in the young population from 1990 to 2019: a population-based study. RMD Open, 9.

Zhu, B., Yi-Wang, Zhou, W., Jin, S., Shen, Z., Zhang, H., Zhang, X., Ding, X., & Li, Y. (2022). Trend dynamics of gout prevalence among the Chinese population, 1990-2019: A joinpoint and age-period-cohort analysis. Frontiers in Public Health, 10.

Ziegler, A., Ladman, B., Dunn, P., Schneider, A., Davison, S., Miller, P., Lu, H., Weinstock, D., Salem, M., Eckroade, R., & Gelb, J. (2002). Nephropathogenic Infectious Bronchitis in Pennsylvania Chickens 1997–2000. Avian Diseases, 46, 847–858.

Zimmerman, H., Bhagwat, M., Laranger, R., Padnick-Silver, L., & LaMoreaux, B. (2023). AB1240 PERCEPTIONS OF GOUT AND ITS MANAGEMENT PATTERNS: FINDINGS FROM SURVEY AND STRUCTURED INTERVIEWS WITH PRIMARY CARE PHYSICIANS AND RHEUMATOLOGISTS. Annals of the Rheumatic Diseases.

Zobbe, K., Prieto-Alhambra, D., Cordtz, R., Højgaard, P., Hindrup, J. S., Kristensen, L., & Dreyer, L. (2019). Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology.

Understanding Allergic Reactions to Allopurinol and Alternative Medications for Gout Management

by | Oct 12, 2024 | Gout, Prescription, Treatment

goutAllopurinol is a commonly prescribed medication for the treatment of gout, a form of arthritis characterized by severe pain, redness, and tenderness in joints. Despite its efficacy, allopurinol can cause allergic reactions in some individuals. This blog will explore the types of people who may have an allergic reaction to allopurinol and discuss alternative medications that can be used to manage gout.

Who is at Risk for Allergic Reactions to Allopurinol?

1. Genetically Susceptible Populations

Certain genetic factors can predispose individuals to allergic reactions to allopurinol. One of the most significant genetic markers is the presence of the HLA-B*5801 allele. This allele is particularly prevalent in specific ethnic groups, including Han Chinese, Thai, and Korean populations. Individuals with this genetic marker are at a higher risk of developing severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when taking allopurinol (Greenberger, 2012, pp. 103–107; Stamp & Barclay, 2018, pp. i35–i41).

2. Patients with Chronic Kidney Disease

Chronic kidney disease (CKD) can increase the risk of allopurinol hypersensitivity syndrome (AHS). The impaired renal function in CKD patients can lead to the accumulation of allopurinol and its metabolites, increasing the likelihood of adverse reactions. Therefore, patients with CKD should be closely monitored when prescribed allopurinol, and alternative treatments should be considered if necessary (Stamp & Barclay, 2018, pp. i35–i41).

3. Individuals with a History of Drug Allergies

Patients with a history of allergic reactions to other medications are more likely to experience an allergic reaction to allopurinol. This includes individuals who have had previous reactions to drugs such as antibiotics, anticonvulsants, and nonsteroidal anti-inflammatory drugs (NSAIDs). A thorough medical history should be taken to identify any potential risks before prescribing allopurinol (Greenberger, 2012, pp. 103–107, 2019, pp. 474–479).

4. Patients with Specific Comorbidities

Certain comorbidities can increase the risk of allergic reactions to allopurinol. For example, individuals with human immunodeficiency virus (HIV) infection, chronic lymphocytic leukemia, and other immunocompromised states are at a higher risk of drug hypersensitivity reactions. These patients should be carefully evaluated before initiating allopurinol therapy (Greenberger, 2012, pp. 103–107, 2019, pp. 474–479).

5. Elderly Patients

Elderly patients are generally more susceptible to adverse drug reactions due to age-related changes in drug metabolism and excretion. The risk of allopurinol hypersensitivity may be higher in this population, necessitating careful dose adjustments and monitoring (Mumoli et al., 2011, pp. 709–710).

 

Alternative Medications for Gout Management

For individuals who cannot tolerate allopurinol due to allergic reactions, several alternative medications can be used to manage gout effectively. These alternatives include febuxostat, probenecid, and pegloticase, among others.

1. Febuxostat

Febuxostat is a xanthine oxidase inhibitor, similar to allopurinol, but with a different chemical structure. It is an effective alternative for patients who are allergic to allopurinol or have not achieved adequate uric acid control with allopurinol. Febuxostat has been shown to be effective in reducing serum uric acid levels and preventing gout flares. It is particularly useful for patients with renal impairment, as it does not require dose adjustments based on renal function (Bardin et al., 2016, pp. 314–317; Ильиных et al., 2017, pp. 83–88).

Efficacy and Safety

Clinical trials have demonstrated that febuxostat is as effective, if not more so, than allopurinol in lowering serum uric acid levels. It has also been associated with a lower risk of severe cutaneous adverse reactions compared to allopurinol. However, febuxostat should be used with caution in patients with cardiovascular disease, as some studies have suggested an increased risk of cardiovascular events with its use (Bardin et al., 2016, pp. 314–317; Ильиных et al., 2017, pp. 83–88).

2. Probenecid

Probenecid is a uricosuric agent that increases the excretion of uric acid in the urine. It is an effective alternative for patients who cannot tolerate xanthine oxidase inhibitors like allopurinol and febuxostat. Probenecid is particularly useful for patients with normal renal function and those who do not have a history of kidney stones (Sivordova et al., 2021).

Efficacy and Safety

Probenecid has been shown to be effective in reducing serum uric acid levels and preventing gout flares. However, it is not suitable for patients with renal impairment or a history of uric acid kidney stones, as it can increase the risk of stone formation. Additionally, probenecid can interact with other medications, so a thorough review of the patient’s medication list is necessary before initiating therapy(Sivordova et al., 2021).

3. Pegloticase

Pegloticase is a recombinant uricase enzyme that converts uric acid to allantoin, a more soluble and easily excreted compound. It is used for the treatment of chronic gout in patients who have not responded to conventional therapies. Pegloticase is administered intravenously and is typically reserved for patients with severe, refractory gout (Sivordova et al., 2021).

Efficacy and Safety

Pegloticase has been shown to be highly effective in reducing serum uric acid levels and resolving tophi in patients with chronic gout. However, it is associated with a risk of infusion reactions and the development of anti-pegloticase antibodies, which can reduce its efficacy over time. Patients receiving pegloticase should be closely monitored for signs of infusion reactions and antibody development (Sivordova et al., 2021).

4. Lesinurad

Lesinurad is a selective uric acid reabsorption inhibitor that works by inhibiting the URAT1 transporter in the kidneys, thereby increasing the excretion of uric acid. It is used in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout. Lesinurad is an option for patients who require additional uric acid-lowering therapy beyond what can be achieved with a xanthine oxidase inhibitor alone (Sivordova et al., 2021).

Efficacy and Safety

Lesinurad has been shown to be effective in combination with allopurinol or febuxostat in reducing serum uric acid levels. However, it is associated with a risk of renal adverse events, including acute renal failure, particularly when used as monotherapy. Therefore, lesinurad should always be used in combination with a xanthine oxidase inhibitor and with close monitoring of renal function(Sivordova et al., 2021).

5. Colchicine

Colchicine is an anti-inflammatory medication that is used to treat acute gout flares and to prevent recurrent flares. While it does not lower serum uric acid levels, it is an important adjunctive therapy for managing the inflammatory component of gout. Colchicine can be used in combination with uric acid-lowering therapies to provide comprehensive gout management(Sivordova et al., 2021).

Efficacy and Safety

Colchicine is effective in reducing the pain and inflammation associated with acute gout flares. It is also used at low doses for flare prophylaxis. However, colchicine can cause gastrointestinal side effects, such as diarrhea and abdominal pain, and should be used with caution in patients with renal or hepatic impairment. Drug interactions should also be considered, as colchicine can interact with several other medications (Sivordova et al., 2021).

 

Conclusion

Allopurinol is a widely used and effective medication for the management of gout, but it can cause allergic reactions in certain individuals. Populations at higher risk for allergic reactions to allopurinol include those with specific genetic markers, chronic kidney disease, a history of drug allergies, certain comorbidities, and elderly patients. For these individuals, alternative medications such as febuxostat, probenecid, pegloticase, lesinurad, and colchicine can be used to manage gout effectively.

It is essential for healthcare providers to carefully evaluate each patient’s risk factors and medical history before prescribing allopurinol or its alternatives. Close monitoring and patient education are crucial to ensure the safe and effective management of gout. By understanding the risks and benefits of each treatment option, healthcare providers can tailor therapy to meet the individual needs of their patients, improving outcomes and quality of life for those living with gout.

References

Abdurrahman, Z., Kastner, M., Wurman, C., Harada, L., Bantock, L., Cruickshank, H., & Waserman, S. (2011). Experiencing a first food allergic reaction: a survey of parent and caregiver perspectives. Allergy, Asthma & Clinical Immunology, 9, 18–18.

Adamcová, M., Šturdík, I., Koller, T., & Payer, J. (2016). [DRESS syndrome]. Vnitrni Lekarstvi, 62 4, 334–337.

Al-kuraishy, H., Al-Gareeb, A., Al-Niemi, M., Aljowaie, R. M., Almutairi, S., Alexiou, A., & Batiha, G. (2022). The Prospective Effect of Allopurinol on the Oxidative Stress Index and Endothelial Dysfunction in Covid-19. Inflammation, 45, 1651–1667.

Anonymous. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021. MMWR. Morbidity and Mortality Weekly Report, 70, 125–129.

Árnadóttir, M. (2014). Febuxostat in adenosine phosphoribosyltransferase deficiency. American Journal of Kidney Diseases, 64 2, 316.

Balakirski, G., & Merk, H. (2017). Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic. Cutaneous and Ocular Toxicology, 36, 307–316.

Bardin, T., Chalès, G., Pascart, T., Flipo, R., Ea, H. K., Roujeau, J., Delayen, A., & Clerson, P. (2016). Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint, Bone, Spine : Revue Du Rhumatisme, 83 3, 314–317.

Bian, S., Li, L., Wang, Z., Cui, L., Xu, Y., Guan, K., & Zhao, B. (2022). Allergic Reactions After the Administration of COVID-19 Vaccines. Frontiers in Public Health, 10.

Blumenthal, K., Robinson, L., Camargo, C., Shenoy, E., Banerji, A., Landman, A., & Wickner, P. G. (2021). Acute Allergic Reactions to mRNA COVID-19 Vaccines. Journal of the American Medical Association (JAMA).

Brinker, A. (2009). Allopurinol and the role of uric acid in hypertension. Journal of the American Medical Association (JAMA), 301 3, 270; author reply 270-1.

Careta, M. F., Delgado, L., & Patriota, R. (2015). Report of Allergic Reaction After Application of Botulinum Toxin. Aesthetic Surgery Journal, 35 5, NP102-5.

Cash, J. C., & Bradbury-Golas, K. (2019). Allergic Rhinitis. Canadian Family Practice Guidelines.

Chu, D., Abrams, E., Golden, D., Blumenthal, K., Wolfson, A. R., Stone, C., Krantz, M., Shaker, M., & Greenhawt, M. (2022). Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis. JAMA Internal Medicine.

Copaescu, A., & Trublano, J. A. (2022). The assessment of severe cutaneous adverse drug reactions. Australian Prescriber, 45, 43–48.

Earll, J., & Saavedra, M. (1983). Oxipurinol therapy in allopurinol-allergic patients. American Family Physician, 28 5, 147–148.

Fam, A. (2001). Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Current Rheumatology Reports, 3, 29–35.

Fine, P., Savrinski, B., & Millodot, M. (2003). Contact lens management of a case of Stevens-Johnson syndrome: a case report. Optometry, 74 10, 659–664.

Fontana, R., Li, Y.-J., Phillips, E., Saeed, N., Barnhart, H., Kleiner, D., & Hoofnagle, J. (2021). Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. Liver International (Print), 41, 1884–1893.

Gb, E. (2020). The Role of Uric Acid Metabolism in Anaphylaxis: the Effect of Allopurinol on Allergic Reactions to Peanut in Peanut Allergic Adults.

Gede, N., Putra, J., Ganesha, R., Ngurah, G., & Dermawan, P. (2023). Identification and treatment of identification and treatment of erythema multiforme induced by allopurinol. Interdental Jurnal Kedokteran Gigi (IJKG).

Godinho, M., Aguinaga, F., Grynszpan, R., Lima, V. M., Azulay, D., Cuzzi, T., Ramos‐e‐Silva, M., & Manela‐Azulay, M. (2015). Granulomatous reaction to red tattoo pigment treated with allopurinol. Journal of Cosmetic Dermatology, 14.

Greenberger, P. (2012). Chapter 30: Drug allergy. Allergy and Asthma Proceedings, 33 Suppl 1, 103–107.

Greenberger, P. (2019). Drug allergy. Allergy and Asthma Proceedings, 40 6, 474–479.

Han, S., Sun, L., He, F., & Che, H. (2017). Anti-allergic activity of glycyrrhizic acid on IgE-mediated allergic reaction by regulation of allergy-related immune cells. Scientific Reports, 7.

Hui-Chen, & Zhang, Q. (2010). The Possible Pathogenesis and Clinic Treatment of Heavy Drug Eruption Caused by Allopurinol. International Medicine and Health Guidance News, 16, 2248–2250.

Kim, M. S., Youn, S., Na, C., & Shin, B. (2015). Allergic reaction to hyaluronidase use after hyaluronic acid filler injection. Journal of Cosmetic & Laser Therapy, 17, 283–285.

Kim, Y.-Y., Je, I., Kim, M. J., Kang, B., Choi, Y.-A., Baek, M., Lee, B., Choi, J. K., Park, H.-R., Shin, T., Lee, S., Yoon, S.-B., Lee, S.-R., Khang, D., & Kim, S.-H. (2016). 2-Hydroxy-3-methoxybenzoic acid attenuates mast cell-mediated allergic reaction in mice via modulation of the FcεRI signaling pathway. Acta Pharmacologica Sinica, 38, 90–99.

Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., Bauer, A., Merk, H., Rabe, U., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., … Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. Allergo Journal International, 30, 51–55.

Kounis, N., Koniari, I., Gregorio, C., Velissaris, D., Petalas, K., Brinia, A., Assimakopoulos, S., Gogos, C., Kouni, S., Kounis, G., Calogiuri, G., & Hung, M.-Y. (2021). Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines, 9.

Kumar, A., & Azmi, W. (2014). Phytomedicine: A novel alternative for treatment of gout.

Kumar, M., Duraisamy, K., & Chow, B. (2021). Unlocking the Non-IgE-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2). Cells, 10.

Kyung, S., Cho, Y., Kim, Y. J., Park, J.-W., Jeong, S., Jae-Lee, Sung, Y. M., & Lee, S. (2011). A Paragonimiasis Patient with Allergic Reaction to Praziquantel and Resistance to Triclabendazole: Successful Treatment after Desensitization to Praziquantel. Korean Journal of Parasitology, 49, 73–77.

Latalski, M., Walczyk, A., Fatyga, M., Rutz, E., Szponder, T., Bielecki, T., & Danielewicz, A. (2019). Allergic reaction to platelet-rich plasma (PRP). Medicine, 98.

Lockard, O., Harmon, C., Nolph, K., & Irvin, W. (1976). Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Annals of Internal Medicine, 85 3, 333–335.

Luxi, N., Giovanazzi, A., Arcolaci, A., Bonadonna, P., Crivellaro, M., Cutroneo, P., Ferrajolo, C., Furci, F., Guidolin, L., Moretti, U., Olivieri, E., Petrelli, G., Zanoni, G., Senna, G., & Trifirò, G. (2022). Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. BioDrugs, 36, 443–458.

Macaulay, S., Bayliff, C., & Mehta, S. (2002). Fluoroquinolone-Induced Acute Interstitial Nephritis: Two Case Reports. The Canadian Journal of Hospital Pharmacy, 55.

Mahase, E. (2020). Covid-19: People with history of significant allergic reactions should not receive Pfizer vaccine, says regulator. British Medical Journal, 371.

Mahipathy, S. R. V., Durairaj, A. R., Sundaramurthy, N., Ramachandran, M., & Natarajan, P. G. (2019). Lyell’s syndrome: a rare case report. International Surgery Journal.

Martínez-Aranguren, R., Gamboa, P., García-Lirio, E., Alonso, A., & Sanz, M. (2012). In vitro cytokine production after in vivo desensitization in an allopurinol-induced delayed allergic reaction. Annals of Allergy, Asthma & Immunology, 108 4, 280–281.

Mathews, H. G., & Tancil, C. G. (1996). Extrapyramidal Reaction caused by Ondansetron. The Annals of Pharmacotherapy, 30, 196–196.

Monti, G., Viola, S., Tarasco, Lupica, M., Cosentino, & Castagno, E. (2011). A case of severe allergic reaction to cooked potato. Acta Paediatrica, 100.

Mumoli, N., Cei, M., Luschi, R., Carmignani, G., & Camaiti, A. (2011). Allergic reaction to Croscarmellose sodium used as excipient of a generic drug. QJM : Monthly Journal of the Association of Physicians, 104 8, 709–710.

Nakao, A., Nakao, A., Nakamura, Y., & Shibata, S. (2015). The circadian clock functions as a potent regulator of allergic reaction. Allergy. European Journal of Allergy and Clinical Immunology, 70, 467–473.

Neki, N., Kumar, J., Jain, A., Bajaj, R., Manav, M., Kumar, H., & Chavan, V. (2016). Allopurinol Induced Stevens – Johnson Syndrome: A Rare Case Report. Kerala Medical Journal, 9, 40–42.

Sampath, V., Rabinowitz, G., Shah, M. M., Jain, S., Diamant, Z., Jeseňák, M., Rabin, R., Vieths, S., Agache, I., Akdiş, M., Barber, D., Breiteneder, H., Chinthrajah, S., Chivato, T., Collins, W., Eiwegger, T., Fast, K., Fokkens, W., O’Hehir, R., … Nadeau, K. (2021). Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives. Allergy. European Journal of Allergy and Clinical Immunology, 76, 1640–1660.

Scavone, C., Mauro, C. D., Ruggiero, R., Bernardi, F., Trama, U., Aiezza, M., Rafaniello, C., & Capuano, A. (2019). Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy. Drugs – Real World Outcomes, 7, 41–51.

Sharma, P., Gupta, N., Hasan, N., Krishnamurthy, B., & Singh, S. (2016). Hypersensitivity with Inhalational Budesonide: An Under Recognised Entity. Journal of Clinical and Diagnostic Research : JCDR, 10 10, FD01–FD02.

Shavit, R., Maoz-Segal, R., Iancovici-Kidon, M., Offengenden, I., Yahia, S. H., Maayan, D. M., Lifshitz-Tunitsky, Y., Niznik, S., Frizinsky, S., Deutch, M., Elbaz, E., Genaim, H., Rahav, G., Levy, I., Belkin, A., Regev-Yochay, G., Afek, A., & Agmon-Levin, N. (2021). Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. JAMA Network Open, 4.

Shimabukuro, T., & Team, C. C.-R. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. MMWR. Morbidity and Mortality Weekly Report, 70, 46–51.

Shittu, M., Shah, P., Elkhalili, W., Suleiman, A., Shaaban, H., Shah, P. A., & Shamoon, F. (2015). A Rare Case of Recurrent Pacemaker Allergic Reaction. Heart Views, 16, 59–61.

Sivordova, L., Polyakova, Y., Papichev, E., Akhverdyan, Y., & Zavodovskii, B. V. (2021). Modern facilities of pharmacological correction of hyperuricemia in rheumatic diseases: management of difficult clinical cases. Meditsinskiy Sovet Medical Council.

Skypala, I., Bartra, J., Ebo, D., Faber, M., Fernández-Rivas, M., Gomez, F., Luengo, O., Till, S., Asero, R., Barber, D., Cecchi, L., Perales, A. D., Hoffmann‐Sommergruber, K., Pastorello, E., Swoboda, I., Konstantinopoulos, A., Ree, R., & Scala, E. (2021). The diagnosis and management of allergic reactions in patients sensitized to non‐specific lipid transfer proteins. Allergy. European Journal of Allergy and Clinical Immunology, 76.

Smith, C. (2023). Allergic Contact Dermatitis. Springer Berlin Heidelberg.

Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M., Barber, D., Giacco, S. D. D., Jutel, M., Nadeau, K., Palomares, Ó., Rabin, R., Riggioni, C., Vieths, S., Agache, I., & Shamji, M. (2021). EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines. Allergy. European Journal of Allergy and Clinical Immunology, 76, 1629–1639.

Sprung, J., Weingarten, T., & Schwartz, L. (2015). Presence or absence of elevated acute total serum tryptase by itself is not a definitive marker for an allergic reaction. Anesthesiology, 122 3, 713–714.

Stamp, L., & Barclay, M. (2018). How to prevent allopurinol hypersensitivity reactions? Rheumatology, 57 suppl_1, i35–i41.

Tohyama, M., & Hashimoto, K. (2001). [Hypersensitivity syndrome and HHV-6]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 59 11, 2285–2292.

Tournikioti, K., Douzenis, A., Antoniadou, A., Papazahos, K., Moschos, C., Papageorgiou, C., & Rizos, E. (2016). Eosinophilia Associated With Olanzapine. Journal of Clinical Psychopharmacology, 36 2, 180–181.

Wang, H., Wang, H., & Liu, Z. P. (2011). Agents that induce pseudo-allergic reaction. Drug Discoveries & Therapeutics, 5 5, 211–219.

Warren, C., Snow, T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., Betts, B., Buzzanco, A., Gonzalez, J. C., Chinthrajah, R., Do, E., Chang, I., Dunham, D., Lee, G. M., O’Hara, R., Park, H. K., Shamji, M., Schilling, L., Sindher, S., … Nadeau, K. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Network Open, 4.

Winter, R., Bent, S. V. D., Esch, M., Wolkerstorfer, A., & Rustemeyer, T. (2019). Allergic Reaction to Red Cosmetic Lip Tattoo Treated With Hydroxychloroquine. Dermatitis.

Ильиных, Е. В., Владимиров, С. А., & Елисеев, М. С. (2017). Фебуксостат в терапии подагры: от теории к практике. Modern Rheumatology Journal, 11, 83–88.

How Your Weight Affects Your Gout Risk: What You Need to Know

How Your Weight Affects Your Gout Risk: What You Need to Know

by | Jun 7, 2024 | Diet, Excercise, Gout

Gout is a form of arthritis that is caused by the buildup of uric acid in the body, leading to the formation of crystals in the joints. These crystals can cause severe pain, swelling, and inflammation, particularly in the big toe. While genetics and diet play a significant role in the development of gout, research has shown that weight also plays a crucial role in increasing the risk of developing this painful condition.

Excess weight can lead to an increase in the production of uric acid in the body, as well as a decrease in the excretion of uric acid through the kidneys. This imbalance can result in higher levels of uric acid in the blood, leading to the formation of crystals in the joints and the development of gout. Additionally, excess weight can also lead to other health conditions such as high blood pressure, diabetes, and heart disease, all of which are risk factors for gout. Therefore, it is essential to understand the impact of weight on gout development and take steps to manage weight to reduce the risk of developing this painful condition.

Key Takeaways

  • Excess weight increases the risk of developing gout
  • Obesity is a major factor in increasing gout risk
  • Managing weight is crucial in preventing and managing gout
  • Body Mass Index (BMI) is closely linked to gout risk
  • Maintaining a healthy weight is key in reducing the risk of gout

The Impact of Excess Weight on Gout Development

Excess weight can have a significant impact on the development of gout. Studies have shown that individuals who are overweight or obese are at a higher risk of developing gout compared to those who maintain a healthy weight. This is because excess weight can lead to an increase in the production of uric acid in the body, as well as a decrease in the excretion of uric acid through the kidneys. This imbalance can result in higher levels of uric acid in the blood, leading to the formation of crystals in the joints and the development of gout.

Furthermore, excess weight can also lead to other health conditions such as high blood pressure, diabetes, and heart disease, all of which are risk factors for gout. In addition, excess weight can also lead to inflammation in the body, which can exacerbate the symptoms of gout and increase the risk of gout attacks. Therefore, it is crucial for individuals who are overweight or obese to understand the impact of their weight on gout development and take steps to manage their weight to reduce their risk of developing this painful condition.

How Obesity Increases Gout Risk

Obesity is a significant risk factor for gout, as it can lead to an increase in the production of uric acid in the body and a decrease in the excretion of uric acid through the kidneys. This imbalance can result in higher levels of uric acid in the blood, leading to the formation of crystals in the joints and the development of gout. Furthermore, obesity is also associated with other health conditions such as high blood pressure, diabetes, and heart disease, all of which are risk factors for gout.

In addition, obesity can also lead to inflammation in the body, which can exacerbate the symptoms of gout and increase the risk of gout attacks. Therefore, it is essential for individuals who are obese to understand the impact of their weight on gout risk and take steps to manage their weight to reduce their risk of developing this painful condition.

The Role of Weight Management in Gout Prevention

Weight management plays a crucial role in gout prevention. By maintaining a healthy weight, individuals can reduce their risk of developing gout by decreasing the production of uric acid in the body and increasing the excretion of uric acid through the kidneys. This can help to prevent the formation of crystals in the joints and reduce the risk of gout attacks.

Furthermore, weight management can also help to reduce inflammation in the body, which can alleviate the symptoms of gout and decrease the frequency of gout attacks. Therefore, it is essential for individuals to focus on maintaining a healthy weight through a balanced diet and regular physical activity to reduce their risk of developing gout.

Weight Loss Strategies for Gout Prevention and Management


There are several effective weight loss strategies that individuals can use to prevent and manage gout. One effective strategy is to focus on making dietary changes that promote weight loss and reduce the production of uric acid in the body. This includes consuming a diet that is low in purines, which are substances that are broken down into uric acid in the body. Additionally, individuals should focus on consuming a diet that is rich in fruits, vegetables, whole grains, and lean proteins, which can help to promote weight loss and reduce inflammation in the body.

In addition to dietary changes, regular physical activity is also essential for weight loss and gout prevention. Engaging in regular exercise can help individuals to burn calories, build muscle mass, and improve their overall health. This can help to promote weight loss and reduce the risk of developing gout. Therefore, it is essential for individuals to focus on making dietary changes and engaging in regular physical activity to prevent and manage gout.

The Connection Between Body Mass Index (BMI) and Gout

Body mass index (BMI) is a measure that is used to assess an individual’s body fat based on their height and weight. Research has shown that there is a strong connection between BMI and gout, with individuals who have a higher BMI being at a greater risk of developing this painful condition. This is because individuals with a higher BMI are more likely to have excess body fat, which can lead to an increase in the production of uric acid in the body and a decrease in the excretion of uric acid through the kidneys.

Furthermore, individuals with a higher BMI are also more likely to have other health conditions such as high blood pressure, diabetes, and heart disease, all of which are risk factors for gout. Therefore, it is essential for individuals to focus on maintaining a healthy BMI through a balanced diet and regular physical activity to reduce their risk of developing gout.

Losing Weight Too Quickly Can Cause Gout Symptoms

Rapid weight loss can lead to an increase in uric acid levels, which in turn can trigger gout symptoms. This is because when the body breaks down fat cells, it releases purines, which are converted into uric acid. Therefore, it is important to lose weight at a steady and healthy pace to avoid exacerbating gout symptoms. A healthy weight management plan is when you have a gradual weight loss that allows the body to properly process and excrete uric acid, reducing the risk of gout flare-ups. Additionally, maintaining a balanced diet and staying hydrated can also help manage uric acid levels and prevent gout symptoms from worsening. It’s important to consult with a healthcare professional before starting any weight loss regimen, especially for individuals with a history of gout or high uric acid levels.

Tips for Maintaining a Healthy Weight to Reduce Gout Risk

There are several tips that individuals can follow to maintain a healthy weight and reduce their risk of developing gout. One important tip is to focus on making dietary changes that promote weight loss and reduce the production of uric acid in the body. This includes consuming a diet that is low in purines and rich in fruits, vegetables, whole grains, and lean proteins. Additionally, individuals should focus on portion control and mindful eating to prevent overeating and promote weight loss.

In addition to dietary changes, regular physical activity is also essential for maintaining a healthy weight and reducing gout risk. Engaging in regular exercise can help individuals to burn calories, build muscle mass, and improve their overall health. This can help to promote weight loss and reduce inflammation in the body. Therefore, it is essential for individuals to focus on making dietary changes and engaging in regular physical activity to maintain a healthy weight and reduce their risk of developing gout.

In conclusion, it is crucial for individuals to understand the link between weight and gout and take steps to manage their weight to reduce their risk of developing this painful condition. By focusing on maintaining a healthy weight through a balanced diet and regular physical activity, individuals can reduce their risk of developing gout and improve their overall health and well-being.

Quenching the Pain: The Surprising Benefits of Water for Gout Relief

Quenching the Pain: The Surprising Benefits of Water for Gout Relief

by | Jun 7, 2024 | Diet, Gout, Safe Foods

Gout is a form of arthritis that occurs when uric acid builds up in the body and forms crystals in the joints, leading to inflammation and intense pain. The condition is often characterized by sudden and severe attacks of pain, swelling, redness, and tenderness in the joints, most commonly in the big toe. Gout can also affect other joints such as the ankles, knees, elbows, wrists, and fingers. The symptoms of gout can be debilitating and can significantly impact a person’s quality of life.

The primary cause of gout is an excess of uric acid in the blood, which can be due to various factors such as genetics, diet, obesity, certain medical conditions, and medications. Foods high in purines, such as red meat, seafood, and alcohol, can contribute to elevated uric acid levels and increase the risk of gout attacks. Additionally, dehydration can also play a role in the development of gout, as it can lead to higher concentrations of uric acid in the blood. It is essential for individuals with gout to understand the causes and symptoms of the condition in order to effectively manage and prevent flare-ups.

Key Takeaways

  • Drinking plenty of water can help reduce gout flare-ups and manage symptoms
  • Gout is caused by the buildup of uric acid in the body, leading to painful joint inflammation
  • Hydration plays a crucial role in managing gout by helping to flush out uric acid from the body
  • Increasing water intake can be achieved through flavored water, herbal teas, and hydrating foods
  • Dehydration can lead to gout attacks, so it’s important to incorporate hydration into a holistic gout management plan


The Role of Hydration in Managing Gout

Hydration plays a crucial role in managing gout as it helps to flush out excess uric acid from the body through urine. When the body is well-hydrated, it is better able to dissolve and excrete uric acid, reducing the risk of crystal formation in the joints. Adequate hydration also helps to maintain proper kidney function, which is essential for eliminating uric acid from the body. Furthermore, staying hydrated can help to reduce inflammation and improve joint mobility, which are important factors in managing gout symptoms.

In addition to its role in uric acid excretion, hydration also helps to prevent the formation of kidney stones, which can be a complication of gout. Kidney stones are solid deposits of minerals and salts that can form in the kidneys when urine becomes concentrated due to dehydration. By staying well-hydrated, individuals with gout can reduce their risk of developing kidney stones and minimize the potential complications associated with the condition. Overall, maintaining proper hydration is essential for managing gout and reducing the frequency and severity of gout attacks.

How Water Helps to Reduce Gout Flare-ups

Water is one of the most effective and natural ways to reduce gout flare-ups. Drinking plenty of water helps to dilute uric acid in the blood and promote its excretion through urine. By increasing urine volume, water helps to prevent the crystallization of uric acid in the joints, which can lead to gout attacks. In addition to its role in uric acid excretion, water also helps to reduce inflammation and provide relief from gout pain. Proper hydration can also improve joint function and mobility, making it easier for individuals with gout to manage their symptoms and maintain an active lifestyle.

Furthermore, staying well-hydrated can help to prevent the recurrence of gout attacks. Dehydration can trigger gout flare-ups by increasing the concentration of uric acid in the blood and promoting crystal formation in the joints. By drinking an adequate amount of water throughout the day, individuals with gout can reduce their risk of experiencing painful attacks and improve their overall quality of life. Water is a simple yet powerful tool for managing gout and should be an essential part of any gout management plan.

Tips for Increasing Water Intake for Gout Relief

There are several strategies that individuals with gout can use to increase their water intake and experience relief from their symptoms. One effective approach is to carry a reusable water bottle with them throughout the day as a reminder to drink water regularly. Setting specific goals for water consumption, such as drinking a certain number of glasses or liters per day, can also help individuals with gout stay on track with their hydration needs. Additionally, incorporating water-rich foods such as fruits and vegetables into their diet can contribute to their overall fluid intake and support their efforts to manage gout.

Another helpful tip for increasing water intake is to flavor water with natural ingredients such as lemon, cucumber, or mint to make it more enjoyable to drink. Some individuals may find it helpful to set reminders or alarms on their phone or computer to prompt them to drink water at regular intervals throughout the day. It is important for individuals with gout to find a hydration strategy that works best for them and to make a conscious effort to prioritize their water intake for optimal gout relief.

Other Hydrating Options for Gout Sufferers


In addition to drinking plain water, there are other hydrating options that individuals with gout can incorporate into their daily routine to support their overall hydration needs. Herbal teas, such as chamomile or ginger tea, can provide a soothing and hydrating alternative to plain water while offering additional health benefits. Coconut water is another hydrating option that is rich in electrolytes and can help individuals with gout stay properly hydrated while replenishing essential nutrients.

Consuming water-rich foods such as cucumbers, watermelon, celery, and lettuce can also contribute to overall hydration and support gout relief efforts. These foods not only provide hydration but also offer essential vitamins, minerals, and antioxidants that can help individuals with gout manage their symptoms and improve their overall health. By incorporating a variety of hydrating options into their daily routine, individuals with gout can ensure that they are meeting their fluid needs and supporting their efforts to manage their condition effectively.

The Link Between Dehydration and Gout Attacks

Dehydration is closely linked to gout attacks as it can lead to higher concentrations of uric acid in the blood and increase the risk of crystal formation in the joints. When the body is dehydrated, it becomes less efficient at excreting uric acid through urine, leading to higher levels of uric acid in the blood. This can trigger gout attacks and exacerbate existing symptoms, making it essential for individuals with gout to prioritize proper hydration as part of their management plan.

Furthermore, dehydration can also contribute to other health issues such as kidney stones, which are a common complication of gout. When urine becomes concentrated due to dehydration, it can lead to the formation of solid deposits of minerals and salts in the kidneys, resulting in kidney stones. By staying well-hydrated, individuals with gout can reduce their risk of developing kidney stones and minimize potential complications associated with the condition. Proper hydration is essential for preventing gout attacks and supporting overall health and well-being.

Incorporating Hydration into a Holistic Gout Management Plan

Incorporating hydration into a holistic gout management plan is essential for effectively managing symptoms and reducing the frequency and severity of gout attacks. In addition to drinking plenty of water throughout the day, individuals with gout should also focus on consuming a balanced diet that includes plenty of water-rich foods such as fruits and vegetables. Avoiding dehydration triggers such as excessive alcohol consumption and sugary beverages can also support efforts to stay properly hydrated and manage gout effectively.

Regular physical activity can also contribute to overall hydration by promoting sweating and increasing fluid intake. Engaging in low-impact exercises such as walking, swimming, or yoga can help individuals with gout maintain joint mobility while supporting their overall health and well-being. Additionally, incorporating stress-reducing activities such as meditation or deep breathing exercises can help individuals with gout manage their symptoms and support their overall hydration needs.

In conclusion, proper hydration plays a crucial role in managing gout by helping to reduce uric acid levels in the blood, prevent crystal formation in the joints, and support overall health and well-being. By understanding the causes and symptoms of gout and incorporating effective hydration strategies into their daily routine, individuals with gout can experience relief from their symptoms and improve their quality of life. It is important for individuals with gout to prioritize proper hydration as part of a holistic management plan that includes a balanced diet, regular physical activity, stress reduction techniques, and other supportive measures. With a comprehensive approach that includes adequate hydration, individuals with gout can effectively manage their condition and minimize the impact of gout on their daily lives.